A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.
The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.
Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.
Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.
NVAX shares were up 3% in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 6.18, Change: +0.18, Percent Change: +3.02
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。